Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors

NCT04721015 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04721015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04721015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First In Human Study Evaluating Safety And Efficacy Of ABBV-637 As Either Monotherapy Or In Combination In Adult Subjects With Relapsed And Refractory Solid Tumors
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 23, 2021
Completion date
February 28, 2026
Enrollment
81 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors cancer, non small cell lung cancer (nsclc)